Milestone Pharmaceuticals (NASDAQ: MIST) CEO sells 43,500 shares of stock

Rhea-AI Filing Summary

Milestone Pharmaceuticals President and CEO Joseph Oliveto reported pre‑planned stock sales under a Rule 10b5-1 trading plan. On January 7, 2026, he sold 500 common shares at $2.25 per share, and on January 8, 2026, he sold an additional 43,000 common shares at $2.25 per share. After these transactions, he directly beneficially owned 303,721 common shares.

The filing notes that the trading plan was adopted on September 30, 2025, which means the sales were scheduled in advance. The reported per-share price on January 8 is a weighted average; the shares were sold in multiple trades at prices ranging from $2.25 to $2.265.

Insider Trade Summary

Net Seller: 43,500 shares ($97,875)

Net Sell 2 txns

Insider Oliveto Joseph

Role President and CEO

Sold 43,500 shs ($98K)

Type	Security	Shares	Price	Value
Sale	Common Shares	43,000	$2.25	$97K
Sale	Common Shares	500	$2.25	$1K

Holdings After Transaction: Common Shares — 303,721 shares (Direct)

Footnotes (1)

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.265 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Oliveto Joseph

(Last) (First) (Middle)

C/O MILESTONE PHARMACEUTICALS INC.

1111 DR. FREDERIK-PHILIPS BLVD, STE 420

(Street)

MONTREAL A8 H4M 2X6

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Milestone Pharmaceuticals Inc. [ MIST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	01/07/2026		S(1)		500	D	$2.25	346,721	D
Common Shares	01/08/2026		S(1)		43,000	D	$2.25(2)	303,721	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.265 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Joseph Oliveto	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider in this Milestone Pharmaceuticals (MIST) Form 4 filing?

The insider is Joseph Oliveto, who serves as President, CEO, and a Director of Milestone Pharmaceuticals Inc.

How many Milestone Pharmaceuticals (MIST) shares did Joseph Oliveto sell?

Joseph Oliveto sold 500 common shares on January 7, 2026, and 43,000 common shares on January 8, 2026, for a total of 43,500 shares.

At what prices were the Milestone Pharmaceuticals (MIST) shares sold in this Form 4?

The January 7, 2026 sale was at $2.25 per share. The January 8, 2026 sale is reported at a weighted average price of $2.25, with trades executed between $2.25 and $2.265 per share.

How many Milestone Pharmaceuticals (MIST) shares does Joseph Oliveto own after these trades?

Following the reported transactions, Joseph Oliveto beneficially owned 303,721 common shares of Milestone Pharmaceuticals Inc., held directly.

Were the Milestone Pharmaceuticals (MIST) insider sales made under a Rule 10b5-1 plan?

Yes. The filing states that the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Joseph Oliveto on September 30, 2025, indicating the sales were pre‑planned.

What does the weighted average price disclosure mean in this Milestone (MIST) Form 4?

The filing explains that the $2.25 price for the January 8, 2026 sale is a weighted average of multiple trades executed at prices from $2.25 to $2.265. The insider has undertaken to provide detailed trade-level pricing upon request.